February 4th 2023
During a live Tweet Chat, Hope S. Rugo, MD, and Paolo Tarantino, MD, reviewed a patient case and discussed current standard of care for those with metastatic triple-negative breast cancer.
Pembrolizumab Granted 4 Approvals in Japan for High-Risk TNBC, RCC, and More
October 2nd 2022Japan’s Ministry of Health, Labor and Welfare approved pembrolizumab for use in 4 indications, including high-risk, early-stage triple-negative breast cancer, stage IIB or IIC melanoma, adjuvant renal cell carcinoma, and recurrent/metastatic cervical cancer.
Treatment with Pembrolizumab/Chemo Combo May Be a Standard of Care in mTNBC
December 7th 2021Patients with previously untreated, locally recurrent, inoperable, or metastatic triple-negative breast cancer derived a statistically significant survival benefit following treatment with pembrolizumab and chemotherapy.
Adding Carboplatin to Neoadjuvant Paclitaxel Improved Outcomes in TNBC
September 18th 2021Although the addition of carboplatin to neoadjuvant paclitaxel followed by cyclophosphamide helped to improve outcomes for those with treatment-naïve triple-negative breast cancer, the addition of veliparib did not have an impact on pathologic complete response or event-free survival.
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
July 27th 2021Based on results of the KEYNOTE-522 trial, the FDA approved pembrolizumab, the first immunotherapy for this indication, plus chemotherapy as neoadjuvant treatment for patients with early-stage triple-negative breast cancer.
Datopotamab Deruxtecan Shows Promise in Heavily Pretreated Triple-Negative Breast Cancer
May 10th 2021The TROP2-directed antibody-drug conjugate datopotamab deruxtecan induced responses and an acceptable safety profile in a cohort of patients with triple-negative breast cancer treated on a phase 1 trial.
FDA Committee Supports Maintaining Accelerated Approval of Atezolizumab in PD-L1+ mTNBC
April 28th 2021The FDA’s Oncologic Drugs Advisory Committee voted 7 to 2 in favor of atezolizumab plus nab-paclitaxel maintaining its accelerated approval to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1.
FDA Issues Complete Response Letter for Pembrolizumab as Neoadjuvant Therapy in Early TNBC
March 30th 2021The FDA’s Oncologic Drugs Advisory Committee voted in favor of waiting for additional event-free survival data to become available before making a regulatory decision regarding a biologics license application for pembrolizumab in early triple-negative breast cancer.
Low-Dose Capecitabine Maintenance Therapy Leads to Improved Disease-Free Survival for TNBC
December 30th 2020Among women with early-stage triple-negative breast cancer who received standard adjuvant treatment, low-dose capecitabine maintenance therapy for 1 year resulted in significantly improved disease-free survival rates compared with observation.
Atezolizumab, Chemo Combo Improves Outcomes Without Adding Treatment Burden in Early TNBC
December 11th 2020Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.